What's Going On With Eli Lilly Stock On Tuesday?
What's Going On With Eli Lilly Stock On Tuesday?
On Tuesday, Eli Lilly and Co (NYSE:LLY) announced a collaboration with Microsoft Corp (NASDAQ:MSFT)-backed OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
禮來公司（Eli Lilly and Co，NYSE：LLY）週二宣佈與微軟公司（Microsoft Corp，NASDAQ：MSFT）支持的OpenAI進行合作，以利用OpenAI的生成式人工智能發明新型抗微生物藥物以治療耐藥病原體。
"Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance," said Diogo Rau, executive vice president and chief information and digital officer at Lilly.
“與OpenAI的合作在抗擊越來越受忽視的抗微生物藥物耐藥威脅方面邁出了具有開創性的一步，”禮來公司執行副總裁兼首席信息和數字官Diogo Rau表示。
Also Read: Eli Lilly's Zepbound For Weight Loss Shows Disease Resolution In Obese Sleep Apnea Patients, Lays Further Groundwork For Label Expansion.
還閱讀：禮來公司的減重藥 Zepbound 在肥胖型睡眠呼吸暫停患者中展示出疾病緩解，爲標籤擴展打下更多基礎。
"Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens. This partnership underscores our commitment to addressing significant health challenges experienced by people around the world."
“生成式人工智能爲在抗擊耐藥病原體方面加速新型抗微生物藥物的發現和開發、以及定製的、特製的技術提供了新的機遇，這一合作彰顯了我們應對全球人民所面臨的重大健康挑戰的承諾。”
Antimicrobial resistance (AMR) affects countries in all regions and at all income levels and is exacerbated by poverty and inequality, particularly in low- and middle-income countries.
抗微生物藥物耐藥性（AMR）影響所有地區和收入水平的國家，貧困和不平等加劇了這種情況，特別是在低收入和中等收入國家。
The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in developing drug-resistant pathogens, magnifying this threat to global health.
人類、動物和植物中對抗微生物藥物的誤用和濫用是發展耐藥病原體的主要驅動力，進一步加劇了這種對全球健康的威脅。
This collaboration with OpenAI supports Lilly's earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio.
與OpenAI的這一合作支持Lilly早期通過其社會影響風險投資組合對抗耐藥病原體的承諾。
In 2020, the portfolio committed $100 million to the AMR Action Fund to provide patients with two to four new antibiotics by 2030 and contribute to the next line of defense against multi-drug-resistant pathogens.
2020年，該投資組合承諾向AMR行動基金（AMR Action Fund）提供1億美元，以在2030年前爲患者提供兩到四種新抗生素，併爲下一代對抗多重藥物耐藥病原體做出貢獻。
In April 2023, the AMR Action Fund announced its latest investments in biotech companies targeting a range of infections.
2023年4月，AMR行動基金宣佈其對針對一系列感染的生物技術公司的最新投資。
In April, Moderna Inc. (NASDAQ:MRNA) announced an ongoing collaboration with OpenAI. Moderna began collaborating with OpenAI in early 2023 with the launch of its own instance of ChatGPT, called mChat. The company announced it has reached more than 80% internal adoption of mChat, accelerating the AI culture at Moderna.
2023年初，Moderna Inc.（納斯達克：MRNA）宣佈與OpenAI展開持續合作，推出其自己的ChatGPT實例，稱爲mChat。公司宣佈已達到超過80％的內部採用率，加速了Moderna的人工智能文化。
Price Action: LLY shares are up 1.30% at $901.69 at the last check on Tuesday.
截至週二最後結算時，LLY股價上漲1.30％，至901.69美元。
Photo via Wikimedia Commons
照片通過Wikimedia Commons
譯文內容由第三人軟體翻譯。